According to Sina Finance, Novartis announced on November 17 that the U.S. Food and Drug Administration approved its drug secukinumab (Cosentyx) for adults with polymyalgia rheumatica (PMR) who do not respond adequately to glucocorticoid treatment or cannot tolerate dose reductions. It is the first interleukin-17 (IL-17) inhibitor approved for PMR and the drug’s 11th approved indication in the United States.
The approval was based on results from the Phase 3 REPLENISH trial. After 24 weeks of gradual glucocorticoid tapering, 40.5% of patients receiving 150 milligrams of secukinumab were in sustained remission at Week 52, compared with 20.5% of those receiving placebo. The results also showed the drug helped reduce patients’ reliance on glucocorticoids.
PMR mainly affects people aged 50 and older and can cause pain and stiffness in the shoulders, neck and hips. Novartis estimates that about 966,000 people in the United States have the condition. The first-year relapse rate can reach 40%, and long-term glucocorticoid use may increase the risk of osteoporosis, cardiovascular disease and diabetes.
The drug’s overall safety profile in the trial was broadly consistent with previous studies, though some adverse events, including hypersensitivity reactions and urinary tract infections, occurred more often than with placebo. The treatment group reported one serious urinary tract infection and one fatal case of cryptococcal meningitis.
Secukinumab is also approved for PMR in the European Union. Regulatory reviews are ongoing in Japan and other markets.